Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dazhu Hongjingtian injection as adjunctive therapy for acute ischemic stroke
ChiCTR2200064448Phase 4Not yet recruiting
- Sponsor
- Institute of Basic Research in Clinical Medicine
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Dazhuhongjingtian in ischemic stroke (2 arms), sponsored by Institute of Basic Research in Clinical Medicine. Primary endpoints: Change in NIHSS score within 7 days of admission and Modified Rankin Scale score at 3 months after enrollment. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
Dazhuhongjingtian
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2200064448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064448.